This article titled 'Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies' analyzes the efficacy and safety of biosimilars compared to original biological medicines in the treatment of patients with psoriasis.

Psoriasis is a chronic skin disease that often requires expensive biological treatments to control symptoms in patients with moderate to severe cases. Biosimilars are similar versions of original biological medications that may offer a more affordable option. However, approval of biosimilars is often based on extrapolation of data from other disorders, raising questions about their efficacy and safety specifically in patients with psoriasis.

To address this question, comprehensive searches of medical databases and clinical trial registries were conducted to identify relevant clinical trials and observational studies related to the use of biosimilars in patients with psoriasis. 14 clinical trials and 3 cohort studies were included in the analysis.

The results of this study indicated that there were no clinically significant differences in efficacy and safety between biosimilars and originator biologic medications in the treatment of psoriasis. This was assessed by comparing the 75% improvement in Psoriasis Area and Severity Index scores and risks of adverse events at 16 and 52 weeks between the patient groups receiving biosimilars and those receiving biologics. originals.

It was observed that both patients who started on biosimilars and those who switched from originator biologics to biosimilars showed no significant differences in efficacy and safety outcomes compared to those who continued on originator biologics. However, a cohort study reported a higher number of adverse events in patients who switched to adalimumab biosimilars at 12 months.

Importantly, the majority of available evidence was based on randomized clinical trials, although the lack of high-quality evidence in real-world settings was acknowledged. Therefore, it was concluded that future studies are needed to examine the long-term effectiveness and safety of biosimilars in the treatment of patients with psoriasis.

In summary, this study suggests that biosimilars may be an effective and safe option in the treatment of psoriasis, but more research is needed to support these findings and better understand their real-world impact.